David Johnson, MD
Pain Medicine · Evansville, INNPI 1902836174
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,193 and has fallen 60.8% since, to $467 in 2025.
Across 175 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$810
- Abbott$716
- Protega Pharmaceutials Inc$448
- Biodelivery Sciences International, Inc.$428
- AbbVie$379
- Amgen$239
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,26298%
- Education$912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 46 | $810 |
| Abbott | 8 | $716 |
| Protega Pharmaceutials Inc | 5 | $448 |
| Biodelivery Sciences International, Inc. | 18 | $428 |
| AbbVie(2 entities) | 18 | $379 |
| Amgen(2 entities) | 10 | $239 |
| Biohaven Pharmaceuticals, Inc. | 4 | $200 |
| Avanir Pharmaceuticals, Inc. | 10 | $192 |
| Indivior Inc. | 9 | $151 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $101 |
| Novartis | 5 | $98 |
| Hikma Pharmaceuticals USA | 5 | $91 |
| Pfizer | 7 | $84 |
| Orexo US, Inc. | 5 | $68 |
| Redhill Biopharma Inc. | 3 | $67 |
| Daiichi Sankyo Inc. | 4 | $60 |
| Virtus Pharmaceuticals LLC | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Zyla Life Sciences, Inc. | 2 | $24 |
| AstraZeneca | 2 | $24 |
| Nevro Corp. | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Pernix Therapeutics Holdings, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Proclaim Family of SCS IPGs$294
- Roxybond$201
- ETERNA$133
- IonicRF$130
- UBRELVY$125
- NURTEC ODT$123
How this compares
$4,353 in reported general payments places this provider in the 55th percentile of 128 pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 440 | $187,179 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 588 | $42,546 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,626 | $21,304 |
| BelbucaBuprenorphine Hcl | 88 | $17,961 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,184 | $17,463 |
| Diclofenac Sodium | 19 | $14,568 |
| MounjaroTirzepatide | 11 | $13,676 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 41 | $13,363 |
| Oxycodone Hcl | 1,101 | $12,734 |
| MovantikNaloxegol Oxalate | 21 | $8,621 |
| OxycontinOxycodone Hcl | 50 | $7,338 |
| Nucynta ErTapentadol Hcl | 24 | $7,005 |
| Hysingla ErHydrocodone Bitartrate | 27 | $4,748 |
| Ondansetron Hcl | 12 | $3,928 |
| Buprenorphine | 20 | $3,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er | $810 | $212,145552 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine | $91 | $45,927608 claims |
| Lilly USA, LLCMounjaro | $13 | $13,67611 claims |
| Orexo US, Inc.Zubsolv | $68 | $13,36341 claims |
| Redhill Biopharma Inc.Movantik | $67 | $8,62121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 128 pain medicine providers in Indiana.
Other pain medicine in Evansville
- Nicolaus WintersEvansville$9K
- Francis McDonnellEvansville$6K
- Joseph FolzEvansville$5K
- Katherine WilliamsEvansville$4K
- Derron WilsonCarmel$616K
- Kevin MacadaegCarmel$337K
- Andrew TrobridgeMuncie$253K
- Meredith LanghorstFishers$233K
- Abhishek DasMishawaka$186K
- Rajiv TewariFishers$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.